Neuroimmunomodulation in Depression: A Review of Inflammatory Cytokines Involved in this Process

Neurochemical Research

Volumn 39, Issue 9, 2014, Pages 1634-1639

  Abelaira, Helena M ^a   Réus, Gislaine Z ^a,b   Petronilho, Fabricia ^b,c   Barichello, Tatiana ^a,b   Quevedo, João ^a,b  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

Antidepressants; Cytokines; Depression; Inflammation

Indexed keywords

AUTACOID; CYTOKINE;

DEPRESSION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOMODULATION; INNATE IMMUNITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CYTOKINES; DEPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; NEUROIMMUNOMODULATION; PITUITARY-ADRENAL SYSTEM;

EID: 84919613140     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1372-5     Document Type: Review

References (90)

1. Duman RS (1998) Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 44:324–335
2. Patel A (2013) Review: the role of inflammation in depression. Psychiatr Danub 25:216–223
3. Nemeroff CB, Owens MJ (2002) Treatment of mood disorders. Nat Neurosci 5:1068–1070
4. Herbert TB, Cohen S, Marsland AL et al (1994) Cardiovascular reactivity and the course of immune response to an acute psychological stressor. Psychosom Med 56:337–344
5. Maes M (2001) The immunoregulatory effect of antidepressants. Hum Psychopharmacol Clin Exp 16:95–103
6. Maes M (1999) Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461:25–46
7. Kushner I (1982) The phenomena of the acute phase response. Ann N Y Sci 389:39–48
8. Smith RS (1991) The macrophage theory of depression. Med Hypotheses 35:298–306
9. Sirisinha S (2011) Insight into the mechanisms regulating immune homeostasis in health and disease. Asian Pac J Allergy Immunol 1:1–14
10. Suvisaari J, Mantere O (2013) Inflammation theories in psychotic disorders: a critical review. Infect Disord Drug Targets 13:59–70
11. Suvisaari J, Loo BM, Saarni SE, Haukka J, Perälä J, Saarni SI, Viertiö S, Partti K, Lönnqvist J, Jula A (2011) Inflammation in psychotic disorders: a population-based study. Psychiatry Res 189:305–311
12. Cruvinel WM, Mesquita DJ, Araújo JAP, Catelan TTT, Souza AW, Silva NP, Andrade LEC (2010) Sistema imunitário—parte i fundamentos da imunidade inata com ênfase nos mecanismos moleculares e celulares da resposta inflamatória. Rev Bras Reumatol 50:434–461
13. Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ (2005) Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B 6:1045–1056
14. Abbas AK, Lichtman AH, Pillai S (2012) Cellular and molecular immunology, 7th edn. Elsevier Saunders, Philadelphia, p 864
15. Janeway CA, Travers P (1997) Immunobiology. The immune system in health and disease, 3rd edn. Current Biol/Garland Publishing, New York
16. Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157:683–694
17. Rezaie P, Trillo-Pazos G, Everall IP, Male DK (2002) Expression of beta-chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS. Glia 37:64–75
18. Lee YB, Nagai A, Kim SU (2002) Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 69:94–103
19. Khairova RA, Machado-Vieira R, Du J, Manji HK (2009) A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 12:561–578
20. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR (2006) Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 30:899–905
21. Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19:11–38
22. Felger JC, Lotrich FE (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199–229
23. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457
24. Kling MA, Alesci S, Csako G, Costello R, Luckenbaugh DA, Bonne O et al (2007) Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry 62:309–313
25. Ford DE, Erlinger TP (2004) Depression and C-reactive protein in US adults: data from the third national health and nutrition examination survey. Arch Intern Med 164:1010–1014
26. Danner M, Kasl SV, Abramson JL, Vaccarino V (2003) Association between depression and elevated C-reactive protein. Psychosom Med 65:347–356
27. Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J et al (2002) Inflammation and coagulation factors in persons N 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 89:419–424
28. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S et al (2008) Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 23:421–429
29. Simen BB, Duman CH, Simen AA, Duman RS (2006) TNF[alpha] signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 59:775–785
30. Malynn S, Campos-Torres A, Moynagh P, Haase J (2013) The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res 38:694–704
31. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al (2001) Cytokineassociated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58:445–452
32. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V (1999) Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiol 40:171–176
33. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol 22:370–379
34. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M (2001) Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 11:203–208
35. Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S et al (2003) Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol Psychiatry 54:566–572
36. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E (2003) Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacol 170:429–433
37. Marques-Deak AH, Neto FL, Dominguez WV, Solis AC, Kurcgant D, Sato F et al (2007) Cytokine profiles in women with different subtypes of major depressive disorder. J Psychiatr Res 41:152–159
38. Palin K, McCusker RH, Strle K, Moos F, Dantzer R, Kelley KW (2008) Tumor necrosis factor-a-induced sickness behavior is impaired by central administration of an inhibitor of c-jun N-terminal kinase. Psychopharmacol 197:629–635
39. Fu X, Zunich SM, O’Connor JC, Kavelaars A, Dantzer R, Kelley KW (2010) Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3-dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation 7:43
40. Kent S, Bluthé RM, Kelley KW, Dantzer R (1992) Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13:24–28
41. Kent S, Bluthé RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ, Vannice JL (1992) Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA 89:9117–9120
42. Kent S, Kelley KW, Dantzer R (1992) Effects of lipopolysaccharide on foodmotivated behavior in the rat are not blocked by an interleukin-1 receptor antagonist. Neurosci Lett 145:83–86
43. Bluthé RM, Michaud B, Poli V, Dantzer R (2000) Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav 70:367–373
44. Ignatowski TA, Chou RC, Spengler RN (1996) Changes in noradrenergic sensitivity to tumor necrosis factor-alpha in brains of rats administered clonidine. J Neuroimmunol 70:55–63
45. Nickola TJ, Ignatowski TA, Reynolds JL, Spengler RN (2001) Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity. J Pharmacol Exp Ther 297:680–687
46. Bayramg€urler D, Karson A, Ozer C, Utkan T (2013) Effects of longterm etanercept treatment on anxiety- and depression-like neurobehaviors in rats. Physiol Behav 119C:145–148
47. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41
48. Kraneveld AD, de Theije CG, van Heesch F, Borre Y, de Kivit S, Olivier B, Korte M, Garssen J (2014) The neuro-immune axis: prospect for novel treatments for mental disorders. Basic Clin Pharmacol Toxicol 114:128–136
49. Pineda EA, Hensler JG, Sankar R, Shin D, Burke TF, Mazarati AM (2012) Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression. Neurotherapeutics 9:477–485
50. Barrientos RM, Higgins EA, Sprunger DB, Watkins LR, Rudy JW, Maier SF (2002) Memory for context is impaired by a post context exposure injection of interleukin-1 beta into dorsal hippocampus. Behav Brain Res 134:291–298
51. Bellinger FP, Madamba S, Siggins GR (1993) Interleukin 1 beta inhibits synaptic strength and long-term potentiation in the rat CA1 hippocampus. Brain Res 628:227–234
52. Curran B, O’Connor JJ (2001) The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience 108:83–90
53. Gibertini M, Newton C, Friedman H, Klein TW (1995) Spatial learning impairment in mice infected with Legionella pneumophila or administered exogenous interleukin-1-beta. Brain Behav Immun 9:113–128
54. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, Yirmiya R (2008) Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13:717–728
55. Oitzl MS, van Oers H, Schobitz B, de Kloet ER (1993) Interleukin-1 beta, but not interleukin-6, impairs spatial navigation learning. Brain Res 613:160–163
56. Pugh CR, Nguyen KT, Gonyea JL, Fleshner M, Wakins LR, Maier SF, Rudy JW (1999) Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res 106:109–118
57. Parsadaniantz SM, Batsche E, Gegout-Pottie P et al (1997) Effects of continuous infusion of interleukin 1 beta on corticotropin-releasing hormone (CRH), CRH receptors, proopiomelanocortin gene expression and secretion of corticotropin, beta-endorphin and corticosterone. Neuroendocrinology 65:53–63
58. Konsman JP, Veeneman J, Combe C, Poole S, Luheshi GN, Dantzer R (2008) Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide. Eur J Neurosci 28:2499–2510
59. Dantzer R (2009) Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 29:247–264
60. Goshen I, Yirmiya R (2009) Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 30:30–45
61. Borkowska P, Kucia K, Rzezniczek S et al (2011) Interleukin-1beta promoter (-31T/C and -511C/T) polymorphisms in major recurrent depression. J Mol Neurosci 44:12–16
62. Baune BT, Dannlowski U, Domschke K et al (2010) The interleukin 1 beta (IL-1β) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 67:543–549
63. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T (2011) IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun 25:1281–1289
64. Herman JP, Cullinan WE (1997) Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 20:78–84
65. Yu S, Holsboer F, Almeida OF (2008) Neuronal actions of glucocorticoids: focus on depression. J Steroid Biochem Mol Biol 108:300–309
66. Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH (2006) The DEX/CRH test-is it better than the DST? Psychoneuroendocrinology 31:889–894
67. Dantzer R (2001) Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933:222–234
68. Larson SJ, Dunn AJ (2001) Behavioral effects of cytokines. Brain Behav Immun 15:371–387
69. Maier SF, Watkins LR (1998) Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 105:83–107
70. Yirmiya R (2000) Depression in medical illness: the role of the immune system. West J Med 173:333–336
71. Anderson G, Kubera M, Duda W, Lasoń W, Berk M, Maes M (2013) Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin andneuroprogression. Pharmacol Rep 65:1647–1654
72. Dandrea M, Donadelli M, Costanzo C, Scarpa A, Palmieri M (2009) MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines. Nucleic Acids Res 37:6681–6690
73. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9:853–858
74. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K et al (2005) IL-6 levels decrease SSRI treatment in patients with major depression. Hum Psychopharmacol 20:473–476
75. O’Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG (2007) Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 41:326–331
76. Himmerich H, Milenovic S, Fulda S, Plumakers B, Sheldrick AJ, Michel TM et al (2010) Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J Psychiatr Res 44:1052–1057
77. Ohgi Y, Futamura T, Kikuchi T, Hashimoto K (2013) Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 103:853–859
78. Réus GZ, Dos Santos MA, Abelaira HM, Ribeiro KF, Petronilho F, Vuolo F, Colpo GD, Pfaffenseller B, Kapczinski F, Dal-Pizzol F, Quevedo J (2013) Imipramine reverses alterations in cytokines and BDNF levels induced by maternal deprivation in adult rats. Behav Brain Res 242:40–46
79. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23:87–94
80. Levine J, Cholestoy A, Zimmerman J (1996) Possible antidepressant effect of minocycline. Am J Psychiatry 153:582
81. Molina-Hernandez M, Tellez-Alcantara NP, Perez-garcia J et al (2008) Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 32:380–386
82. Lichtenstein GR, Bola M, Man C, DeWoody K, Schaible T (2002) Infliximab improves the quality of life in patients with Crohn’s disease. Inflamm Bowel Dis 8:237–243
83. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L et al (2009) Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 66:287–292
84. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J (2009) Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 33:722–726
85. Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G et al (2006) Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 67:1760–1766
86. Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36:764–785
87. Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M (2011) In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35:744–759
88. Shenoy AR, Dehmel T, Stettner M, Kremer D, Kieseier BC, Hartung HP, Hofstetter HH (2013) Citalopram suppresses thymocyte cytokine production. J Neuroimmunol 262:46–52
89. Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B (2009) The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol 12:525–536
90. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R (2010) Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum 62:683–693